554 – Drug Combination Studies: From Discovery to Clinical
Experimental Design for In Vitro Drug Combination Studies
Huaihou Chen
Columbia University
Gregory Hather
Millennium: The Takeda Oncology Company
Ray Liu
Millennium: The Takeda Oncology Company
In vitro drug combination studies typically involve a large number of wells with various concentrations of two drugs added together. To gain the most information from an experiment, what should the drug concentrations be? Here, we consider the case where the single drug response curves are known beforehand, but no previous data is available from the combination. We consider several designs, including C and D-optimal designs, and a factorial design. We evaluate these designs based on the expected variance of the synergy score for a large set of in vitro experiments performed at Millennium. Based on the results, we were able to identify which design was the most efficient and robust.
